La Jolla-based Singlera Genomics has raised $60 million in a Series A+ round, which will go toward development and commercialization of its non-invasive genetic tests for early-stage cancer detection and clinical validation studies.

Green Pine Capital Partners and Prosperico Ventures led the financing, with participation from new and existing investors, UCF Medical Investment, Jointown Pharmaceutical Group, Lilly Asia Ventures and others.

The funds will also further expand its research facilities and its TiTanSeq and Monod platforms into new product lines for cancer detection, diagnosis and personalized treatment.

The company, founded in 2014, currently has research and development centers and business operations in both La Jolla and Shanghai, China. In 2016, it raised $20 million in a Series A round.

Singlera Genomics in a news release touted “remarkable progress” in applying high-throughput sequencing of circulating tumor DNA to detecting and diagnosing early-stage cancer.